discuss item hss financial reporting as of november 0th, 2017. panel 11. >> panel 11 chief financial officer deputy director. this will be a very quick analysis of this report. the report today summarizes the actual revenues and expenses of the employee benefit trust fund and the general fund to november 2017 as well as the projection through june 30th. in terms of the trust, we will go back and look at what the trust fund balance was on june 30th, 2017, in that 72.5 million. based on the activity through november 2017, we are projecting the fun and the year at 72 million. this is a change of less than 1%. we continue to see unfavorable claims experienced through the medical plans and favorable claims for the dental plans. we received 1.1 million in pharmacy rebates from blue shield ask we are projecting a savings in the $3 budget. no performance guarantees have been received this fiscal year. we have two additional reimbursements associate associated with adoption and service assistants plans but the payments have not yet occurredde, and the amo

that had an average cost for hss of over $700 per 30-day supply. another version of that same medication cost over $4,000 per prescription. and then the brand version of that medication, called gl lumetzglumetza cost $6,500. if you look at the medication by population that only cost $7 per prescription. so we really want to drivualization towardif lent medication but at a lower cost. >> we've had these discussions in the past over drugs and many times the members would say that i guess there are different binders and many have different drugs. they claim they are the same but they are not, i guess. >> we are just following the fda guidelines on approved medications. on further illustration of this slide on slide 1, the agents where doxopene hydro chloride would be moving from tier 1 to tier 3 where the cros cross crotozome. these are examples and commissioner scott i heard your request. and we will get back to you. >> thank you. >> moving on to slide 8. so based on the utilization of hss in calendar year 2017 for the impacted prescriptions on the v

we call it -- often refer to it as to the four employers but it's to all hss members. the charges reflected in the rate card under expense. so when you go through that you will see that, when we present the rate cards and both. employer an pretirery -- based on the insurance moll so i gave the example of the 1993 and 83 and the 100100% for the employee only to show you how much the division is between the employee and the employer. alternative members pay into the health care sustainability funds and benefits from the $3 are available to all of those who paid into the fund. and in the 1819 and 1920 budget that we will be discussing, we categorize it into the following categories, personnel, communications, well-being and initiatives that reduce the cost of health care for all members. are there any questions? >> you say the employees -- microphone. >> you say the employees share. what about retirees? because they are not picked up by the unions. >> right. they are based on whatever the formula is. so for instance if it's tim county, then they have a different formula.

a as tool for hss to help manage riding drug cost. the new full nature structured as i illustrated. will be named tiers 1 through 4 and a clinical medical committee, the pharmacy committee and the valiant medications based on the clinical value and cost effectiveness, not truly on the drug type. whether it's a generic drug or brand medication. >> is this a group within blue shield itself or is it a consultive body to you? >> good question. so the group is come prized the network physicians and clinical pharmacists not employed by blue shield and the blue shield employees do not have any voting privileges. >> randy scott: so it's almost a third party review for this process. >> yes. >> randy scott: i think that's important. because it sounded like when you said it, we are going kind of blur the lines and move these things around. and we are going to do it. so i'm happy to see at least there's some attempt to put it outside the process when you exceeded the recommendations for your group. is that the idea? >> the committee evaluates med

this committee has worked to push the federal government and hss in particular to meet these challenges. an hss that fosters innovation in the development of medical counter measures and across papa's framework provides the greatest hope to ensure the safety of the american people. the witnesses we have before us today will be able to provide insight into the urgency of this mission and the promise innovation holds if properly leveraged. i look forward to hearing from each of you about the progress that we've made and where we can continue to improve policies and programs to realize their full potential to save americans' lives. now i'd like to turn to senator murray for any comments she might have. >> thank you very much, and thank you to all of you for joining this hearing on our nation's preparedness to combat public health threats as we look towards now reauthorizing the pandemic and all hazards preparedness act later this year. i especially want to thank senator casey and senator burr for their bipartisan work and leadership on this really important issue. local washington state pa

t tes iastokinhcr 13 2 f a t phl like hssthis a bl ler k,part f sl nyovements. and onmber 29gains d dicause of him,you b he hs, hink ultimatelvaencean heyorpr a roamy dth tac beca"endanty, a ds r champions, athe nfl to discuss what's ne re. owol mmoney sathat is thhting on@& things